Skip to main content

Table 3 Toxicity in patients treated with nab-paclitaxel (N = 31)

From: A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer

Toxicity Grade1/2 % Grade3 % Grade 4 % Grade3/4 %
Leukopenia 21 67.7 6 19.3 1 3.2 7 22.5
Neutropenia 17 54.8 6 19.3 6 19.3 12 38.6
Anemia 25 80.6 1 3.2 0 0 1 3.2
Thrombocytopenia 5 16.1 0 0 0 0 0 0
Febrile neutropenia   4 12.9
Nausea/vomiting 5 16.1 2 6.4 0 0 2 6.4
Anorexia 10 32.2 1 3.2 0 0 1 3.2
Infection 7 22.5 3 9.6 1 3.2 4 12.9
Neuropathy 19 61.2 3 9.6 0 0 3 9.6
Fatigue 22 70.9 0 0 0 0 0 0
Liver dysfunction 10 32.2 1 3.2 0 0 1 3.2
Diarrhea 6 19.3 0 0 0 0 0 0
Hyperkalemia 7 22.5 0 0 0 0 0 0
Edema 0 0 1 3.2 0 0 0 0